Aldose Reductase and Alcar Trials
Tolerstat: Primary: nerve morphometry and sorbitol content; Secondary: NCV, clinical exam (12 mo analysis no sural effect); some effect on MNCV
Zopolrestat (FK-366): Phase III primary endpoints as Tolerstat, ˝ dose of II, 18 mo interim analysis-no effect
Alcar: Primary: Nerve morphometry and NCS—no effect